1887
Rapid communication Open Access
Like 0

Abstract

SARS-CoV-2 variants of concern (VOC) should not escape molecular surveillance. We investigated if SARS-CoV-2 rapid antigen tests (RATs) could detect B.1.1.7 and B.1.351 VOCs in certain laboratory conditions. Infectious cell culture supernatants containing B.1.1.7, B.1.351 or non-VOC SARS-CoV-2 were respectively diluted both in DMEM and saliva. Dilutions were analysed with Roche, Siemens, Abbott, nal von minden and RapiGEN RATs. While further studies with appropriate real-life clinical samples are warranted, all RATs detected B.1.1.7 and B.1.351, generally comparable to non-VOC strain.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.16.2100413
2021-04-22
2021-12-03
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.16.2100413
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/16/eurosurv-26-16-2.html?itemId=/content/10.2807/1560-7917.ES.2021.26.16.2100413&mimeType=html&fmt=ahah

References

  1. Chand M, Hopkins S, Dabrera G, Achison C, Barclay W, Ferguson N, et al. Investigation of novel SARS-COV-2 variant, Variant of Concern 202012/01. [Accessed 1 Apr 2021]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf
  2. World Health Organization Regional Office for Europe (WHO/Europe), European Centre for Disease Prevention and Control (ECDC). Methods for the detection and identification of SARS-CoV-2 variants. Stockholm: ECDC; Copenhagen: WHO/Europe. [Accessed 1 April 2021]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf
  3. World Health Organization (WHO). SARS-CoV-2 Variants. Geneva: WHO. [Accessed 1 Apr 2021]. Available from: https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/
  4. Mautner L, Baillie C-K, Herold HM, Volkwein W, Guertler P, Eberle U, et al. Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol J. 2020;17(1):160.  https://doi.org/10.1186/s12985-020-01435-6  PMID: 33087160 
  5. Eberle U, Wimmer C, Huber I, Neubauer-Juric A, Valenza G, Ackermann N, et al. , Bavarian SARS-CoV-2-Public Health Laboratory Team. Comparison of nine different commercially available molecular assays for detection of SARS-CoV-2 RNA. Eur J Clin Microbiol Infect Dis. 2021;1-6.  https://doi.org/10.1007/s10096-021-04159-9  PMID: 33512617 
  6. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, et al. Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. medRxiv. 2020.  https://doi.org/10.1101/2020.11.12.20230292 
  7. Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, et al. The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. J Clin Med. 2021;10(2):328.  https://doi.org/10.3390/jcm10020328  PMID: 33477365 
  8. US Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients. Silver Spring: FDA. [Accessed 1 Apr 2021]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes
  9. European Commission Press Corner. Coronavirus: Commission puts forward rules on rapid antigen tests and secures 20 million tests for Member States. [Accessed 1 April 2021]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2483
  10. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9.  https://doi.org/10.7717/peerj.10666  PMID: 33505806 
  11. Babb de Villiers C, Blackburn L, Cook S, Janus J. SARS-CoV-2 Variants. 2021. [Accessed 1 Apr 2021]. Available from: https://www.finddx.org/wp-content/uploads/2021/03/COVID-variants-report-FINAL-12MAR2021.pdf
  12. Azad GK. Identification and molecular characterization of mutations in nucleocapsid phosphoprotein of SARS-CoV-2. PeerJ. 2021;9:e10666.  https://doi.org/10.7717/peerj.10666  PMID: 33505806 
  13. Coronavirus antiviral and resistance database Stanford University. Spike variants. [Accessed 1 Apr 2021]. Available from: https://covdb.stanford.edu/page/mutation-viewer/#b.1.1.7.aka.501y.v1.variant.20i.501y.v1.and.uk.covid.variant
  14. Public Health England (PHE). Guidance SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01. London: PHE. [Accessed 1 Apr 2021]. Available from: https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201
  15. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med. 2020;383(22):e120.  https://doi.org/10.1056/NEJMp2025631  PMID: 32997903 
/content/10.2807/1560-7917.ES.2021.26.16.2100413
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error